Synergism between fibronectin and transforming growth factor-β1 in the production of substance P in monocytes of patients with myelofibrosis

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 631-638

  Chang, Victor T ^a,b   Yook, Clara ^b   Rameshwar, Pranela ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Fibronectin; Myelofibrosis; Neurokinin; NF B; Substance P

Indexed keywords

FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; NEUROKININ 1 RECEPTOR; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOCYTE; MYELOFIBROSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; TAC1 GENE;

ADOLESCENT; AGED; ANIMALS; CELL LINE; CELLS, CULTURED; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRONECTINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1ALPHA; MIDDLE AGED; MONOCYTES; PRIMARY MYELOFIBROSIS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; U937 CELLS; YOUNG ADULT;

EID: 84873394763     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.722218     Document Type: Article

References (45)

1. Rameshwar P, Oh HS, Yook C, et al. Substance p-fbronectin-cytokine interactions in myeloproliferative disorders with bone marrow fbrosis. Acta Haematol 2003;109: 1-10.
2. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29: 573-582.
3. Hussein K, Theophile K, Dralle W, et al. MicroRNA expression prof ling of megakaryocytes in primary myelof brosis and essential thrombocythemia. Platelets 2009: 20: 391-400.
4. Shehata M, Schwarzmeier JD, Hilgarth M, et al. TGF-b1 induces bone marrow reticulin f brosis in hairy cell leukemia. J Clin Invest 2004;113: 676-685.
5. Rameshwar P, Chang VT, Tacker UF, et al. Systemic trans-forming growth factor-beta in patients with bone marrow f brosis-pathophysiological implications. Am J Hematol 1998;59: 133-142.
6. Rameshwar P, Narayanan R, Qian J, et al. NF-kB as a central mediator in the induction of TGF-b1 in monocytes from patients with idiopathic myelof brosis: an inf ammatory response beyond the realm ofhomeostasis. JImmunol 2000;165: 2271-2277.
7. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofbrosis. Br JHaematol 1994;88: 9-16.
8. Sato M, Muragaki Y, Saika S, et al. Targeted disruption ofTGF-b1/Smad3 signaling protects against renal tubulointerstitial f brosis induced byunilateral ureteral obstruction. J Clin Invest 2003;112: 1486-1494.
9. Arribillaga L, Dotor J, Basagoiti M, et al. Therapeutic Effect of a peptide inhibitor of TGF-[beta] on pulmonary fbrosis. Cytokine 2011;53: 327-333.
10. Komura E, Tonetti C, Penard-Lacronique V, et al. Role for the nuclear factor kB pathway in transforming growth factor-b1 production in idiopathic myelof brosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005: 65: 3281-3289.
11. Rosenkranz MA. Substance P at the nexus of mind and body in chronic inf ammation and afective disorders. Psychol Bull 2007: 133: 1007-1037.
12. Joshi DD, Dang A, Yadav P, et al. Negative feedback on the Effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood 2001;98: 2697-2706.
13. Katayama I, Nishioka K. Substance P augments f brogenic cytokine-induced f broblast proliferation: possible involvement of neuropeptide in tissue fbrosis. J Dermatol Sci 1997;15: 201-206.
14. Munoz M, Covenas R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med 2010: 10: 305-313.
15. Pavlovic S, Liezmann C, Blois SM, et al. Substance P is a key mediator of stress-induced protection from allergic sensitization via modifed antigenpresentation. JImmunol 2011;186: 848-855.
16. Vink R, van den Heuvel C. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury. Neurotherapeutics 2010: 7: 74-80.
17. Rameshwar P, Joshi DD, Yadav P, et al. Mimicry between neurokinin-1 and f bronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fbrosis. Blood 2001;97: 3025-3031.
18. Klassert TE, Patel SA, Rameshwar P. Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link. J Receptor Ligand Channel Res 2010: 2010: 51-61.
19. Nakanishi S. Substance Pprecursor and kininogen: theirstructures, gene organizations, and regulation. Physiol Rev 1987;67: 1117-1142.
20. Greco SJ, Rameshwar P. MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proc Natl Acad Sci USA 2007: 104: 15484-15489.
21. Liu K, Castillo MD, Murthy RG, et al. Tachykinins and hematopoiesis. Clin Chim Acta 2007;385: 28-34.
22. Kohara H, Tajima S, Yamamoto M, et al. Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 2010;31: 8617-8625.
23. Harrison NK, Dawes KE, Kwon OJ, et al. Effects of neuropeptides on human lung f broblast proliferation and chemotaxis. Am J Physiol Lung Cell Mol Physiol 1995;268: L278-L283.
24. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelof brosis. Leuk Res 2007: 31: 1503-1509.
25. Barosi G. Myelof brosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17: 2954-2970.
26. Lim PK, Bliss SA, Patel SA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 2011: 71: 1550-1560.
27. Qian J, Yehia G, Molina CA, et al. Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5'-monophosphate response elements in its expression by IL-1 and stem cell factor. J Immunol 2001;166: 2553-2561.
28. Rameshwar P, Chang VT, Tacker UF, et al. Systemic trans-forming growth factor-beta in patients with bone marrow f brosis-pathophysiological implications. Am J Hematol 1998;59: 133-142.
29. Rameshwar P, Gascon P, Bandari PS, et al. Structural similarity between the bone marrow extracellular matrix protein and neurokinin 1 could be the limiting factor in the hematopoietic Effects of substance P. Can J Physiol Pharmacol 2002;80: 475-481.
30. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118: 401-408.
31. Barbui T, Tiele J, Passamonti F, et al. Initialbonemarrowreticulin f brosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119: 2239-2241.
32. Teferi A. Pathogenesisofmyelof brosis with myeloid metaplasia. J Clin Oncol 2005;23: 8520-8530.
33. Teferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelof brosis: a comprehensive cytokine prof ling study. J Clin Oncol 2011;29: 1356-1363.
34. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofbrosis. Blood 2007;110: 986-993.
35. Greco SJ, Smirnov SV, Murthy RG, et al. Synergy between the RE-1 silencer of transcription and NFkB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. J Biol Chem 2007;282: 30039-30050.
36. Rameshwar P, Gascon P. Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood 1996: 88: 98-106.
37. Teferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelof brosis: a comprehensive cytokine prof ling study. J Clin Oncol 2011;29: 1356-1363.
38. Munoz M, Covenas R. NK-1receptorantagonists: anewparadigm in pharmacological therapy. Curr Med Chem 2011;18: 1820-1831.
39. Koon HW, Shih D, Karagiannides I, et al. Substance P modulates colitis-asscociated fbrosis. Am J Pathol 2010;177: 2300-2309.
40. Marriott I, Bost KL. Substance P diminishes lipopolysaccharide and interferon-[gamma]-induced TGF-[beta]1 production by cultured murine macrophages. Cell Immunol 1998: 183: 113-120.
41. Beinborn M, Blum A, Hang L, et al. TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. Proc Natl Acad Sci USA 2010;107: 4293-4298.
42. Sun J, Ramnath RD, Zhi L, et al. Substance P enhances NF-kB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol 2008;294: C1586-C1596.
43. Saban MR, Nguyen NB, Hammond TG, et al. Gene expression prof ling of mouse bladder inf ammatory responses to LPS, substance P, and antigen-stimulation. Am J Pathol 2002: 160: 2095-2110.
44. Marriott I, Mason MJ, Elhofy A, et al. Substance P activates NF-κB independent of elevations in intracellular calcium in murine macrophages and dendriticcells. JNeuroimmunol 2000;102: 163-171.
45. Rameshwar P, Denny TN, Stein D, et al. Monocyte adhesion in patients with bone marrow f brosis is required for the production of f brogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol 1994;153: 2819-2830.